Recent reports highlight FDA leadership moves to limit advisory committee meetings for drug approvals, raising concerns about reduced external oversight. Concurrently, tensions emerge as U.S. pressures the U.K. regarding its stringent drug pricing policies, causing pharma investment pauses in the U.K. Monte Rosa Therapeutics and Novartis announced a collaboration utilizing protein degrader technology despite this challenging regulatory climate. The evolving landscape of regulatory practices and international pricing disputes may reshape global pharma investment and approval dynamics.